Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data from IMPAACT P1110 presented at CROI 2017.
Previous studies have shown raltegravir (RAL) elimination to be highly variable in the first weeks of life due to low UGT1A1 activity.
IMPAACT P1110 is a phase I multicentre study in full-term HIV-1 exposed neonates at high risk of HIV with or without maternal RAL exposure. It includes two cohorts: cohort 1 infants received two single RAL doses one week apart; cohort 2 infants received daily RAL dosing for first six weeks of life.
The study sites are in Brazil, South Africa and the US.
PK data from cohort 1 and from older infants and children in IMPAACT P1066 were combined in a population PK model. The model included maturation of absorption rate from 16% of max at birth to 90% at two weeks, and clearance from close to nil to max at approximately six months of age.
The model was used to perform simulations of possible daily dosing regimens for RAL-naive infants in cohort 2 (using oral granules for suspension). See Table 1.
Exposure targets are: AUC24 12-40 mg*h/L; AUC12 6-20 mg*h/L; C12 or C24 > 33 ng/mL; and Cmax <8724 ng/mL.
Cohort 2 enrolled 26 infants: 46% female; 69% black, 12% white and 19% other; median gestation age 38.5 weeks and birth weight 2.93 kg. Evaluable PK and 6-week safety data were available for 25 infants.
The investigators reported no drug related adverse events. All RAL exposure targets were met; PK parameters are shown in Table 2.
Infants born to mothers who received RAL and low birth weight infants are to be studied in IMPAACT P1110.
Clarke DF et al. Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study. CROI 2017.13-17 February 2017. Seattle. Poster abstract 757.
VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.